Ilc~purlrncwr o!/'t'c~diurric..s. L'ni~~c~r.sify of' A~inncsoru. .Ifinnc,upoli.v. ,bfit~no~o~u 5. 5455 ABSTRACT. We developed a model for the translocation of intraluminal endotoxin in the neonatal animal and used it to examine the capacity of a nonhepatotoxic bile acid, ursodeoxycholic acid (UDCA), to modify endotoxin translocation and cytokine response. Three-d-old SpragueDawley rats were randomized to receive enterally either no drug, lipopolysaccharide (LPS, 1 mdanimal), or UDCA (400 pg/animal) alone, or UDCA followed by LPS 1 h later. One h after LPS administration, the rats were killed and plasma endotoxin and tumor necrosis factor (TNF) were measured. Control animals had low circulating endotoxin (21.2 f 7.6 endotoxin units) and TNF (0.06 f 0.02 ng/mL). Enteral administration of LPS 1 h before the rats were killed resulted in significant elevation of endotoxin (249.5 f 71.3, p = 0.008) and TNF (3.6 f 1.3, p = 0.019).
ABSTRACT. We developed a model for the translocation of intraluminal endotoxin in the neonatal animal and used it to examine the capacity of a nonhepatotoxic bile acid, ursodeoxycholic acid (UDCA), to modify endotoxin translocation and cytokine response. Three-d-old SpragueDawley rats were randomized to receive enterally either no drug, lipopolysaccharide (LPS, 1 mdanimal), or UDCA (400 pg/animal) alone, or UDCA followed by LPS 1 h later. One h after LPS administration, the rats were killed and plasma endotoxin and tumor necrosis factor (TNF) were measured. Control animals had low circulating endotoxin (21.2 f 7.6 endotoxin units) and TNF (0.06 f 0.02 ng/mL). Enteral administration of LPS 1 h before the rats were killed resulted in significant elevation of endotoxin (249.5 f 71.3, p = 0.008) and TNF (3.6 f 1.3, p = 0.019).
UDCA alone did not alter endotoxin levels (8.7 f 2.1). UDCA 1 h before LPS prevented the rise in endotoxin (38.9 f 11.2 endotoxin units) and TNF (0.2 f 0.05) significantly. Chenodeoxycholic acid was studied in a similar group of experiments and prevented neither the translocation of LPS nor the development of increased TNF levels in animals receiving LPS. In conclusion, LPS can cross the intestinal barrier in the normal neonatal rat. UDCA, administered before LPS, can decrease the translocation of LPS and prevent the cytokine response as measured by TNF levels. We speculate that UDCA, administered prophylactically, might reduce morbidity in clinical conditions leading to gut-derived endotoxemia. (Pediatr Res 35: 214-217, 1994) Abbreviations EU, endotoxin unit LPS, lipopolysaccharide TNF, tumor necrosis factor UDCA, ursodeoxycholic acid Endotoxin, a component of the outer membrane of gramnegative bacteria, is well established as a major mediator of vascular injury, leading to multisystem organ failure and death (1). The systemic effects of circulating endotoxin are mediated predominantly through the stimulation of mononuclear cells to produce TNF, IL-I, IL-6, colony-stimulating factors, and eicosanoids. Of these mediators, TNF has been shown to play a central role in the development of systemic hypotension and vascular insufficiency, which ihitiates many of endotoxin's adverse effects (2).
The biologically active portion of endotoxin is LPS, a complex structure of 0-specific polysaccharides. core polysaccharides, and lipid A. Parenterally administered purified LPS reproduces the systemic effects of injected endotoxin (2). For the purposes of this study, we will use the term LPS to refer to purified bacterial lipopolysaccharides and the term endotoxin to refer to the crude outer membrane of gram-negative bacteria. This is a modification of the convention of van Deventer ct al. (3).
The large reservoir of gram-negative bacteria in the intestine has been implicated as a source of endotoxin in several clinical conditions in adults (4). Similar studies in newborns and premature infants have suggested that gut-derived endotoxemia may play a role in the complications of sepsis, necrotizing enterocolitis, and total parenteral nutrition-associated cholestasis in this age group (5-7). In this study. we establish a model to study gutderived endotoxemia in neonatal animals and use the model to examine a therapy to prevent translocation of endotoxin. Intraluminal bile acids have been suggested as a treatment for endotoxemia in adults (8). UDCA is a relatively hydrophilic bile acid with fewer potential side effects than traditional ox bile preparations (9). Our study shows that UDCA can reduce or prevent gut-derived endotoxemia in neonatal animals. This represents a first step toward assessing the potential for this drug to modify the outcome of human neonatal disease associated with increased endotoxin translocation.
MATERIALS A N D M E T H O D S
Muterials. All chemicals were purchased from Sigma, St. Louis, MO, unless otherwise noted. LPS was derived from Eschcrichia coli serotype 055:B5, phenol extracted.
Animals. All animal studies were approved by the University of Minnesota Animal Care and Use Committee. Sprague-Dawley rat dams were purchased from Taconic. Germantown. NY. Within 24 h of delivery, litters were equalized by cross-fostering and culling to produce litters of approximately 10 pups each. At 3 d, pups were separated from their mothers for 1 h and kept warm and dry. After 1 h of starvation, LPS, UDCA (provided by Ciba-Giegy Corp.. Summit, NJ), chenodeoxycholic acid, or a combination of these was administered according to the research protocol via an orogastric tube of 1.78 mm external diameter (Tygon tubing). LPS was administered in a dose of 1 mg/animal (100A in normal saline with 1.0% bromphenol blue), UDCA at 400 pg/animal (10X in ethanol). and chenodeoxycholic acid at 400 pg/animal( I OX in ethanol). The orogastric tube was removed between treatments. Animals were killed by decapitation. and plasma was collected and frozen at -20°C.
Endotoxin and TNF assavs. LPS was measured in plasma using a chromogenic limulus amoebocyte lysate test (BioWhittaker Inc., Walkersville, MD). The detection limit is 0.1 EU. All samples were measured in at least two dilutions: all dilutions were run in duplicate. We demonstrated that concentrations of UDCA 4-fold those of LPS did not affect the results of the assay (OD for 25 pg LPS in NaCl was 1.106: with 0. I ng of UDCA in ethanol, it was 1.16 + 0.02 I ) . TNF was measured by ELISA (Genzyme Corp.. Cambridge. MA). All data were UDCA MODIFIES GUT-DERIVED ENDOTOXEMIA analyzed by one-way analysis of variance and Fischer protected least significant difference on a Macintosh computer with Statview (Abacus Concepts, Inc.. Berkeley. CA). Results are expressed as the mean + SEM.
RESULTS
Animal n~eight.~ and response to oroga.~tricJi>~>din~s. The mean animal weight at 3 d was 9.3 + 0.1 g ( n = 98) (no weight was recorded for two animals). Between experimental groups. there was no significant difference in pup weights, except for that of the group receiving LPS alone (9.0 + 0.3 g) compared with the group receiving UDCA alone (10.4 + 0.6 g). However, linear regression analysis detected no correlation between pup weight and circulating endotoxin levels ( R 2 = 0.18), indicating that the difference in weight had no influence on endotoxin levels. Correct placement of the orogastric tubes was assessed by the appearance of a blue blush in the animals' stomachs during infusion. Animals tolerated orogastric feedings well, although they exhibited temporary lethargy after the insertion of the orogastric tube.
Enteral LPS is translocated into the hlood.str~~am in infant rats. Figure 1 shows the levels of circulating endotoxin in neonatal rats administered enteral LPS. Rats who received no LPS had negligible levels of LPS in their plasma (2 1.2 + 7.6 EU. n = 12).
Rats who received LPS I h before they were killed had significantly elevated levels of plasma endotoxin (249.5 + 7 1.3 EU. n = 17, p = 0.008). Although plasma endotoxin levels were elevated in animals receiving LPS 2 and 4 h before the rats were killed. they were not significantly different from those of controls.
UDCA drcrease.~ LPS translocation , / k m intctstinr in infant rats. To determine whether enteral UDCA could suppress translocation of enteral endotoxin into the bloodstream. we examined animals receiving UDCA 1 or 2 h before administration of LPS. Figure 2 shows that animals receiving UDCA alone had very low levels of circulating endotoxin (8.7 f 2.1 EU, n = 6). These levels were no different than those of animals receiving no endotoxin. Animals receiving UDCA 1 h before administration of LPS (2 h before they were killed) had levels of circulating endotoxin (38.9 k 1 1.2, n = 14) no different from animals receiving UDCA alone Endotoxin levels in neonatal animals treated with UDCA before LPS. Experimental group I received UDCA alone. I h before they were killed, n = 6 : group 2 received LPS alone I h before they were killed (n = 17) (these are the same animals as in Fig. I. group 2 ) . group 3 received UDCA 2 h before LPS or 3 h before they were killed ( t~ = 6 ) . and group 4 received UDCA I h before LPS or 2 h before they were killed ( t i = 14). Significant differences from the LPS only control group are marked with an u.v~c~ri.~k.
Control
LPS -1 h UDCA -2h LPS -1 h Experimental Group Fig. 3 . Plasma TNF levels in neonatal animals after enteral LPS and UDCA. Experimental group I (control) received no treatment (,I = 6). group 2 received LPS alone ( n = 9), and group 3 received UDCA I h before LPS or 2 h before they were killed ( t i = 7). Significant differences from the LPS only control group are marked with an (i.r~i,ri.,k.
Experimental Group
and significantly different from those of animals receiving LPS alone ( p = 0.007). Administration of UDCA 2 h before LPS (3 Fig. 1 . Endotoxin levels in neonatal animals after enteral LPS. Ex-h before they were killed) had no effect on circulating LPS levels.
perimental group 1 (control) received no therapy (!I = 12). group 2
UDCA decreases TNFprodlcction in rats rc~cc~ivitzg ctltcrul LPS.
received LPS I h before they were killed (n = 17). group 3 received LPS Because TNF is the major mediator of the systemic effects of 2 h before they were killed (n = 4). and group 4 received LPS 4 h before endotoxin, we examined whether enterally administered UDCA they were killed ( n = 4). Significant differences from the control group could inhibit the effects of circulating endotoxin to increase (group I ) are marked with an us~crisk. plasma TNF levels. As shown in Figure 3 , control animals had 3 AND BUNDY negligible plasma levels of TNF (0.06 + 0.02 ng/mL, n = 6).
Administration of enteral LPS 1 h before the rats were killed significantly increased circulating TNF levels (3.6 + 1.3 ng/mL, n = 9, p = 0.019). Administration of UDCA 2 h before administration of LPS reduced levels of TNF to levels similar to those of the control animals (0.2 + 0.05 ng/mL, n = 7).
Chenodeoxycholic acid fails lo reduce LPS translocation.
To determine whether a more hydrophobic bile acid, chenodeoxycholic acid, could produce results similar to those seen with UDCA, we examined the effect of chenodeoxycholic acid feeding on enteral translocation of LPS. Results are shown in Figure 4 . Rats fed chenodeoxycholic acid alone had circulating levels of endotoxin similar to those of rats fed LPS alone (69.7 + 20.7 EU, n = 12 compared with 146.4 + 43.8 EU, n = 9, p = 0.15).
Administration of chenodeoxycholic acid before administration of LPS had no effect on circulating levels of endotoxin (1 56.4 + 52.9 EU, n = 8). Similar results were obtained for plasma TNF levels (chenodeoxycholic acid alone, 0.7 + 0.1 ng/mL, n = 6; LPS alone 0.6 + 0.1 ng/mL, n = 3; and chenodeoxycholic acid before administration of LPS, 0.9 + 0.2 ng/mL, n = 4; p = 0.4).
DISCUSSION
Gut-derived endotoxemia has been implicated in a spectrum of adverse effects ranging from isolated hepatic or renal injury to vascular insufficiency leading to multisystem organ failure and death ( I , 4, 8) . The common factor linking diseases associated with gut-derived endotoxemia is increased transit of endotoxin from the gut lumen, seen in diseases resulting in intestinal degeneration or inflammation, ethanol ingestion, or intestinal vascular insufficiency (4). Gut-derived endotoxemia has also been seen in cholestatic conditions, including bile duct obstruction (8) or prolonged administration of total parenteral nutrition (10).
In neonates, endotoxemia has been linked to complications in several diseases. Scheifele el al. have shown that endotoxemia is present in neonates with gram-negative bacterial sepsis (I I), small-bowel overgrowth ( 12), and necrotizing enterocolitis ( 13). This group specifically demonstrated that the thrombocytopenia associated with necrotizing enterocolitis was correlated with the LPS -1 h CDCA -1 h CDCA -2h LPS -1 h Experimental Group Fig. 4 . Endotoxin levels in neonatal animals treated with chenodeoxycholic acid (CDCA) before LPS. Experimental group I received LPS alone 1 h before they were killed ( n = 9). group 2 received CDCA alone I h before they were killed ( n = 12). and group 3 received CDCA I h before LPS or 2 h before they were killed ( n = 8). No significant differences were seen among any of the three groups.
presence of circulating endotoxin (14). Endotoxemia may also be a factor in the development of total parenteral nutritionassociated cholestasis in neonates (7). Experimental studies in rats have led to the suggestion that endotoxin might contribute to the development of giant cell or neonatal hepatitis (15). Although in some cases the source of endotoxemia in neonates is an abscess or another extragastrointestinal source, many times the source is gut-derived endotoxin (5).
For several reasons, neonates may experience both increased translocation of endotoxin from the intestine and increased complications associated with circulating endotoxin compared with adults. The neonatal small bowel can take up macromolecules more readily than the adult small bowel. This uptake is nonselective, probably the result of pinocytosis. Although many of these macromolecules are destroyed within the enterocyte. some reach the systemic circulation (16). If large quantities of endotoxin are present in the neonatal small bowel, there may be an increased risk of endotoxin translocating into the systemic circulation. Secondly. neonates have lower intraluminal bile salt concentrations than do adults, with premature infants particularly affected (7. 17. 18). Because bile acids appear to disrupt endotoxin ( 19), reducing its translocation from the intestine (8, 20) . factors that reduce intestinal bile salt concentration may increase the risk of endotoxin translocation. These physiologic factors may in part explain the observations of Scheifele cJf a/.
(6), who detected endotoxemia in 60% of neonates admitted to a tertiary care facility. Normal levels of luminal bile acids and low levels of macromolecule uptake by the gut in adult rats may explain why endotoxin is not passively absorbed from the gut in normal adult rats (20) and why it is necessary to induce malnutrition, bums, or hypotension to induce bacterial translocation in adult rats (2 1).
In addition, the clinical response to endotoxemia is different in neonates compared with adults. Zeller er al. (22) showed that 10-d-old rats were 300 times as sensitive to the effects of endotoxin, as measured by mortality, as 28-d-old rats. Several developmental factors could account for this increased sensitivity to the effects of circulating endotoxin, including reduced reticuloendothelial system activity in the neonate (23) and differences in neonates compared with adults in the glucoregulatory and hemodynamic regulatory changes associated with endotoxemia (5).
Because of the differences between neonates and adults in their capacity to translocate endotoxin and their responses to systemic endotoxin, it is important to study the effects of gut-derived endotoxemia directly in the neonate. Our study showed that neonatal rats can serve as a model for the uninduced absorption of endotoxin in the newborn. This model provided an opportunity to examine the role of bile acids in preventing gut-derived endotoxemia in neonatal rats. In particular, we were interested in developing a therapy that might be safe and useful over the long periods of time that premature and full-term infants could be at risk for endotoxemia.
Several lines of evidence suggest that intraluminal bile acids might prevent translocation of endotoxin. Kocsar el al. (20) showed that sodium deoxycholate could decrease the absorption of endotoxin from the peritoneal cavity of rats by 47%. Sodium deoxycholate also prevented the absorption of enterally administered tritiated endotoxin in rats. This was thought to be caused by the capacity of sodium deoxycholate to fragment endotoxin into smaller, nontoxic particles (19). although it is not clear why these smaller fragments would not be absorbed. Studies are needed to determine the mechanism by which bile acids modify intestinal absorption of endotoxin, whether the effect is the result of direct action of the bile acid on the endotoxin or the result of alterations in intestinal motility or absorptive capacity. Because endotoxin was implicated in renal failure associated with the postoperative management of patients with obstructive jaundice, Cahill (24) administered sodium deoxycholate 48 h before surgery to a group of patients with obstructive jaundice. The treated group had less endotoxemia and reduced incidence of renal
